Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to $28.1 million.

  • Tg Therapeutics' Cost of Revenue rose 20074.94% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.0 million, marking a year-over-year increase of 15200.71%. This contributed to the annual value of $38.5 million for FY2024, which is 17235.16% up from last year.
  • Per Tg Therapeutics' latest filing, its Cost of Revenue stood at $28.1 million for Q3 2025, which was up 20074.94% from $18.9 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Cost of Revenue ranged from a high of $28.1 million in Q3 2025 and a low of $2000.0 during Q3 2022
  • Moreover, its 5-year median value for Cost of Revenue was $6.6 million (2023), whereas its average is $8.2 million.
  • As far as peak fluctuations go, Tg Therapeutics' Cost of Revenue soared by 26170000.0% in 2023, and later surged by 9606.57% in 2024.
  • Over the past 5 years, Tg Therapeutics' Cost of Revenue (Quarter) stood at $139000.0 in 2021, then plummeted by 97.84% to $3000.0 in 2022, then soared by 261700.0% to $7.9 million in 2023, then skyrocketed by 96.07% to $15.4 million in 2024, then skyrocketed by 82.43% to $28.1 million in 2025.
  • Its last three reported values are $28.1 million in Q3 2025, $18.9 million for Q2 2025, and $15.5 million during Q1 2025.